Skip to main content

Table 3 Clinical efficiency of epigenetic drugs agents in PTCL

From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Drug Patients distribution Response
(ORR, DOR, CR)
Phase
Chidamide [54] N = 79
PTCL-NOS (34%), ALCL (20%),
ENKTL: (20%)
ORR:28%
Median PFS: 2.1 months OS:21.4 months
CR/Cru:14%
Median DOR: 9.9 month
II
Chidamide-Combined Chemotherapy [56] N = 127 ORR = 51.18%
DCR = 74.02%
Median PFS = 152 day
II
Chidamide [56] N = 383 PTCL monotherapy (n = 256) Monotherapy
ORR = 39.06%
DCR = 64.45%,
median (PFS) = 129 days
II
Vorinostat [60] combination with chop N = 14 Median PFS = 79%
OS = 82%
Median response duration = 29 months
I
Romidepsin [66, 67] N = 130 ORR = 25%
CR/Cru = 15%
median PFS = 13.4 ~ 29 months. median DOR = 28 months
II
Romidepsin [68] N = 47 PTCL ORR = 38%,CR = 18% median DOR = 8.9 months II
Romidepsin plus chop [70] N = 37 ORR = 69%
PFS = 41%
OS = 71%,
Ib/II
Pralatrexate + Romidepsin [72] N = 29 ORR = 71% (10/14) II
Romidepsin [73] N = 27
AITL
ORR = 33%  
Belinostat [74] N = 24 PTCL ORR = 25%,
CR = 8%, DOR = 13.6mo
II
Belinostat [75, 76] N = 129 ORR (CR, PR) = 25.8%
Median DoR = 13.6 months Median PFS = 1.6 months
Median OS = 7.9 months
II
5-Azacytidine [125, 126] N = 12 ORR = 75%,
median PFS = 15 months median OS = 21 months
Clinic trial
  1. AITL angioimmunoblastic T-cell lymphoma, PTCL peripheral T-cell lymphoma, Median PFS median progression-free survival, OS overall survival, DOR duration of response, Median DOR median duration of response, CR complete response, DCR disease control rate, PTCL-NOS PTCL not otherwise specified, ALCL anaplastic large-cell lymphoma, ENKTL extranodal natural killer (NK)/T-cell lymphoma, nasal type